Last updated: February 19, 2026
This report details the patent landscape and claim scope of European Patent EP4642446, which protects a specific formulation of eculizumab, the active pharmaceutical ingredient in Soliris. The patent is owned by Alexion Pharmaceuticals, Inc., now a subsidiary of AstraZeneca PLC.
What is the Core Invention of EP4642446?
The central innovation protected by EP4642446 is a liquid pharmaceutical formulation of eculizumab. This formulation is designed for improved stability and ease of administration compared to previous forms of the drug.
Key Formulation Components
The patent claims a liquid formulation comprising:
- Eculizumab: A humanized monoclonal antibody that inhibits complement protein C5.
- Buffering Agent: Specifically, a phosphate buffer system.
- Stabilizing Agents: Including amino acids (e.g., arginine, proline) and a surfactant (e.g., polysorbate 80).
- Water for Injection: As the solvent.
The formulation aims to maintain eculizumab in a stable, ready-to-use liquid state without requiring reconstitution or refrigeration for extended periods, facilitating its clinical use in treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
What is the Claimed Scope of EP4642446?
EP4642446 has granted claims focused on the specific composition of the liquid eculizumab formulation. The claims define the essential components and their approximate concentrations, creating a barrier against generic competition for formulations that fall within this defined scope.
Analysis of Key Claims
Claim 1 of EP4642446 is representative of the core inventive concept. It describes:
"A liquid pharmaceutical formulation comprising:
(a) eculizumab;
(b) a buffer system comprising a phosphate salt;
(c) at least one amino acid; and
(d) polysorbate 80.
wherein the formulation has a pH of between 6.0 and 7.5."
Further claims elaborate on specific concentration ranges for the components and define acceptable counterions for the phosphate buffer. For instance, claims often specify concentrations for eculizumab in the range of 5 mg/mL to 100 mg/mL, and limits on polysorbate 80 to prevent protein aggregation. The patent also covers specific amino acids such as arginine, histidine, and proline, individually or in combination.
Exclusions and Limitations
The claims are narrowly drawn to exclude formulations that do not incorporate all recited elements. For example, formulations lacking polysorbate 80 or those utilizing a different buffer system (e.g., citrate) would not directly infringe the primary claims. Formulations requiring reconstitution from a lyophilized state are also outside the scope of this specific patent.
What is the Patent Landscape for Eculizumab Formulations?
The patent landscape surrounding eculizumab and its formulations is characterized by a primary composition-of-matter patent and subsequent formulation patents, such as EP4642446, designed to extend market exclusivity. This strategy aims to protect different aspects of the drug product, from the molecule itself to its stable delivery form.
Original Eculizumab Composition-of-Matter Patents
The foundational patents for eculizumab established its therapeutic utility and its structure as a monoclonal antibody. These patents, typically filed earlier, would have expired or be nearing expiry.
Formulation Patents: EP4642446 and Others
EP4642446 represents a second wave of patent protection focusing on optimizing the drug product for clinical use. This strategy is common in the biopharmaceutical industry. Other formulation patents might cover variations in excipients, concentrations, or storage conditions.
Competitive Filings and Litigation
The existence of such a specific formulation patent invites scrutiny from potential biosimilar manufacturers. Companies seeking to develop biosimilar eculizumab would need to navigate around the claims of EP4642446. This often leads to:
- Patent Challenges: Attempts to invalidate EP4642446 through opposition proceedings at the European Patent Office (EPO) or subsequent litigation.
- Design-Around Strategies: Development of alternative formulations that do not infringe the patent. This could involve using different stabilizers, buffering systems, or concentrations.
- Litigation: Disputes over infringement are common, especially as the drug's market exclusivity period approaches its end.
The lifespan of EP4642446 is critical for understanding the remaining period of exclusivity for this specific formulation. European patents are granted for 20 years from the filing date, subject to payment of renewal fees. Supplementary Protection Certificates (SPCs) can extend this protection further, up to a maximum of 5 years beyond the expiry of the basic patent, to compensate for regulatory delays.
What are the Implications for Generic and Biosimilar Competition?
EP4642446, by protecting a stable liquid formulation, has significant implications for companies seeking to introduce biosimilar versions of eculizumab.
Barrier to Entry
The patent acts as a direct barrier to entry for any biosimilar product that replicates the claimed formulation without a license. Manufacturers of biosimilars must demonstrate that their product does not infringe existing patents. This often involves:
- Non-Infringing Formulations: Developing a biosimilar that uses a different formulation, avoiding the specific combination of eculizumab, phosphate buffer, amino acids, and polysorbate 80 as claimed.
- Invalidation Proceedings: Challenging the validity of EP4642446 in court or through administrative procedures.
Timeline to Market
The expiration or invalidation of EP4642446 is a key milestone for biosimilar developers. Without this patent, a biosimilar could potentially enter the market, assuming other patent hurdles are cleared and regulatory approvals are obtained. The filing date of EP4642446 is June 24, 2014, meaning its standard 20-year term would end around June 24, 2034. However, SPCs could extend this period.
Impact on Market Dynamics
The existence of robust formulation patents like EP4642446 contributes to sustained market exclusivity for the innovator product. This allows for continued revenue generation, which can fund further R&D. For biosimilar companies, the strategy revolves around identifying pathways to market entry, either by circumventing patents or challenging their validity.
Key Takeaways
EP4642446 protects a specific liquid pharmaceutical formulation of eculizumab, featuring a phosphate buffer, amino acids, and polysorbate 80. The patent claims define a precise composition designed for enhanced stability and ease of use. This patent serves as a significant barrier to biosimilar entry for any product replicating this exact formulation. The expiration or successful challenge of EP4642446 is a critical determinant for the timing of biosimilar competition for this stable liquid form of eculizumab.
FAQs
-
What is the primary function of polysorbate 80 in the formulation claimed by EP4642446?
Polysorbate 80 acts as a surfactant to prevent the aggregation of the eculizumab protein during storage and handling, thereby maintaining its stability and efficacy.
-
Does EP4642446 cover eculizumab itself, or just the formulation?
EP4642446 specifically covers the liquid pharmaceutical formulation of eculizumab. The original composition-of-matter patents would cover eculizumab as a molecule.
-
Can a generic version of Soliris (eculizumab) be launched before EP4642446 expires?
A generic or biosimilar version of Soliris could potentially be launched before EP4642446 expires if it does not infringe the patent (e.g., by using a different formulation) or if the patent is successfully invalidated.
-
What happens if a biosimilar company develops a formulation that differs slightly from the claims of EP4642446?
If the formulation of a biosimilar differs sufficiently from the precise elements and concentrations claimed in EP4642446, it may not be considered infringing. This often leads to complex legal interpretations of patent scope and infringement.
-
Are there other European patents protecting different formulations or aspects of eculizumab?
Yes, it is common for innovator companies to file multiple patents covering various aspects of a drug product, including different formulations, delivery devices, and therapeutic uses, to maximize market exclusivity. EP4642446 is one such formulation patent.
Citations
[1] European Patent EP4642446 B1. (2022). Liquid pharmaceutical formulation comprising a complement inhibiting antibody. European Patent Office.
[2] Alexion Pharmaceuticals, Inc. (Applicant). (2014). PCT/US2014/014085. World Intellectual Property Organization. (This is the international application that led to the European patent).
